358 related articles for article (PubMed ID: 12930162)
1. Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.
Lembo A; Weber HC; Farraye FA
Drugs; 2003; 63(18):1895-905. PubMed ID: 12930162
[TBL] [Abstract][Full Text] [Related]
2. Alosetron and irritable bowel syndrome.
Mayer EA; Bradesi S
Expert Opin Pharmacother; 2003 Nov; 4(11):2089-98. PubMed ID: 14596662
[TBL] [Abstract][Full Text] [Related]
3. Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?
Andresen V; Hollerbach S
Drug Saf; 2004; 27(5):283-92. PubMed ID: 15061683
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
5. [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
Komoto S; Miura S
Nihon Rinsho; 2006 Aug; 64(8):1487-90. PubMed ID: 16898618
[TBL] [Abstract][Full Text] [Related]
6. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Lewis JH
Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
[TBL] [Abstract][Full Text] [Related]
7. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Brenner DM; Sayuk GS
Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
[TBL] [Abstract][Full Text] [Related]
9. The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome.
Nakai A; Diksic M; Kumakura Y; D'Souza D; Kersey K
Neurogastroenterol Motil; 2005 Apr; 17(2):212-21. PubMed ID: 15787942
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
Ford AC; Brandt LJ; Young C; Chey WD; Foxx-Orenstein AE; Moayyedi P
Am J Gastroenterol; 2009 Jul; 104(7):1831-43; quiz 1844. PubMed ID: 19471254
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
[TBL] [Abstract][Full Text] [Related]
13. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
Lewis JH
Drug Saf; 2011 Jul; 34(7):545-65. PubMed ID: 21663331
[TBL] [Abstract][Full Text] [Related]
14. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
De Ponti F; Tonini M
Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
[TBL] [Abstract][Full Text] [Related]
17. Peripherally acting therapies for the treatment of irritable bowel syndrome.
Saad RJ
Gastroenterol Clin North Am; 2011 Mar; 40(1):163-82. PubMed ID: 21333906
[TBL] [Abstract][Full Text] [Related]
18. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
Mangel AW; Northcutt AR
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():77-82. PubMed ID: 10429745
[TBL] [Abstract][Full Text] [Related]
19. 5-HT
El-Ayache N; Galligan JJ
Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G132-G143. PubMed ID: 30359082
[TBL] [Abstract][Full Text] [Related]
20. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.
Chey WD; Cash BD
Expert Opin Investig Drugs; 2005 Feb; 14(2):185-93. PubMed ID: 15757394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]